Topics

Companies Related to "Trial of Surgical Excision Margins in Thick Primary Melanoma - 2" [Most Relevant Company Matches] RSS

20:54 EDT 2nd April 2020 | BioPortfolio

Here are the most relevant search results for "Trial of Surgical Excision Margins in Thick Primary Melanoma - 2" found in our extensive corporate database of over 50,000 company records.

Showing "Trial Surgical Excision Margins Thick Primary Melanoma" Companies 1–25 of 2,600+

Relevant

Polynoma LLC

Malignant melanoma is the most serious form of skin cancer. An estimated 200,000 new cases of melanoma are diagnosed annually around the world, with about 76,000 in the United States alone. The melanoma market is estimated to be in excess of US$1 billion, with the U.S. and Europe being the primary markets.


AIM at Melanoma

AIM at Melanoma, founded in memory of Charlie Guild, who died of melanoma at the age of 26, is the largest international melanoma foundation focused on melanoma research, patient advocacy, legislation, education and awareness. The foundation supports melanoma research efforts by hosting international research forums and is helping to create the first melan...

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...


InCytu Incorporated

InCytu is a privately held biotherapeutic company with its primary operations located in Rhode Island. The Company is targeting its Cellarium vaccine at treating late stage melanoma tumors while gathering promising preliminary data using the Cellarium to treat other cancers. InCytu has established a manufacturing facility for creating Cellarium devices in ...

Melanoma Research Alliance (MRA)

MRA is a public charity formed in 2007 under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. Due to the ongoing support of its founders, 100% of every dollar MRA raises goes to support its melanoma research program. The organization is poised to build on recent momentum in the field, accelerating the pace o...

Trial Acceleration Institute, Inc.

Trial Acceleration Institute collaborates with the entire spectrum of clinical trial stakeholders to improve study cycle times. Assisting stakeholders with actionable resolutions to their specific cycle time challenges (from protocol feasibility to patient retention) via the identification and initiation of best-of-class, third-party solutions is the primary mission of Trial Acceleration Institute...

Melanoma Research Alliance

MRA is a public charity formed in 2007 under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. MRA is poised to build on recent momentum in the field, accelerating the pace of scientific discovery and translation in order to eliminate suffering and death due to melanoma. MRA’s ability to fund wide-ran...

The Melanoma Research Alliance

MRA is a public charity formed in 2007 under the auspices of the Milken Institute, with the generous founding support of Debra and Leon Black. MRA is poised to build on recent momentum in the field, accelerating the pace of scientific discovery and translation in order to eliminate suffering and death due to melanoma. MRA’s ability to fund wide-ranging ...

Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its lead oncology agent, PV-10, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic liver cance...

Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of pri...

SafeStitch Medical, Inc.

Miami-based SafeStitch Medical, Inc. is a medical device company primarily developing endoscopic and minimally invasive surgical devices. SafeStitch product portfolio includes the AMID Stapler™, endoscopic gastroplasty devices for bariatric (obesity) surgery and repair of gastroesophageal reflux disorder (GERD), a standard bite block, an airway bite b...

First Surgical Partners Inc.

First Surgical Partners Inc. (“First Surgical”) operates two ambulatory surgery centers and a general acute care hospital in the Houston area. The surgeons that utilize First Surgical’s facilities perform non life-threatening surgeries at these locations. The procedures performed include bariatric, reconstructive and cosmetic plastics, orthopedics,...

RF Surgical Systems Inc.

RF Surgical Systems, Inc. is the market leader in the detection and prevention of retained surgical items. The RF Surgical Detection System is the preferred solution in more than 300 U.S. hospitals and surgical centers. A number of US News & World Report "Honor Roll" hospital recipients recently joined the fast-growing list of care providers benefiting fro...

ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treat...

For RF Surgical RF Surgical

RF Surgical Systems, Inc. is the market leader in the prevention and detection of retained surgical sponges. The RF Surgical Detection System is the preferred solution in more than 1,000 operating rooms, trauma and labor & delivery suites nationwide. RF Surgical Systems is based in Bellevue, Washington with R & D facilities in San Diego, California. The ad...

Viralytics Limited

Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market (VRACY). Focused on developing oncolytic virotherapy for the treatment of a wide range of cancers Viralytics' headquarters are in Sydney, Australia and research and operations are in Newcastle, Australia. Oncolytic virotherapy makes use of the cancer destroyi...

Broadleaf Industries

P4 was developed over a decade ago in response to the demands of farmers and nursery growers who needed a soil amendment which could outperform conventional potting soils and organic amendments relative to their water holding, releasing, and water saving capacity.P4 represents the latest technical advance in horticultural and agricultural polymers and is by far the leading product of its kind on t...

Progen Pharmaceuticals

Progen Pharmaceuticals Limited (NASDAQ:PGLA; ASX: PGL) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics. The company has an intimate understanding of the role of heparan sulfate, a complex sugar, in cancer disease processes and have developed a small-molecule drug development program i...

RF Surgical, Inc.

RF Surgical Systems, Inc. is the market leader in the detection and prevention of retained surgical sponges. The RF Surgical Detection System is the preferred solution in more than 1,500 operating rooms, trauma and labor and delivery suites nationwide. Since January 2011, more than 80 hospitals and surgical centers have joined the fast-growing list of care...

SolaranRx, Inc.

SolaranRx, Inc. is developing a platform of new therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics—often referred to as theranostics—constitutes a new level of personalized medicine for treating metastatic melanoma. SolaranRx seeks to improve treatment and patientsâ€...

First Surgical Partners, Inc.

First Surgical operates two ambulatory surgery centers and a general acute care hospital in the Houston area. The surgeons that utilize First Surgical’s facilities perform non-emergency surgeries at these locations. The procedures performed include bariatric; ear, nose and throat; reconstructive and cosmetic plastics, orthopedics, pain management, neu...

X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and cancer. X4’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate, X4P-001, is in a Ph...

SolaranRx

SolaranRx, Inc. is developing a platform of new therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics—often referred to as theranostics—constitutes a new level of personalized medicine for treating advanced melanoma. SolaranRx seeks to improve treatment and patients’...

Cigna and Medical Professional Services

Medical Professional Services, Inc. (MPS) is one of Connecticut’s largest multi-specialty independent physician associations (IPA). MPS members include primary care, medical and surgical specialists, and hospital based physicians who are dedicated to providing exceptional medical and surgical care to residents throughout Connecticut. MPS corporate off...

RF Surgical Systems, Inc.

RF Surgical Systems is the market leader in the prevention and detection of retained surgical sponges with more hospitals in service than any other competing technology. The RF Surgical Detection System is the preferred solution in more than a 1,000 Operating Rooms, Trauma and L&D suites nationwide.


More From BioPortfolio on "Trial of Surgical Excision Margins in Thick Primary Melanoma - 2"

Quick Search

Corporate Database Quicklinks